New trial aims to cure HER2+ breast cancer with smart, adaptive therapy

NCT ID NCT07459673

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a personalized approach for people with HER2+ metastatic breast cancer. Doctors use ctDNA blood tests and imaging to decide when to step up or down treatments, including targeted drugs and local therapies, to achieve long-term remission. The goal is to see if this strategy can lead to lasting remission and possibly a cure for some participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fam-trastuzumab deruxtecan-nxki (T-DXd) and pertuzumab
What this could lead to: If successful, this approach could lead to long-lasting remission and possibly cure for some people with HER2+ metastatic breast cancer by personalizing treatment and preventing brain metastases.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The treatment involves multiple drugs and procedures, which can cause side effects, and the personalized strategy may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CANCER STAGE IV HER2-POSITIVE BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activites)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering at Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering at Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering at Westchester (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.